Foghorn CSO granted 300,000 stock options

Foghorn Therapeutics Inc. reported that Chief Scientific Officer Steven F. Bellon received a stock option grant covering 300,000 shares of common stock at an exercise price of $5.71 per share on January 30, 2026.

Accepted by SEC EDGAR 02/02/2026 - 04:01 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. reported that Chief Scientific Officer Steven F. Bellon received a stock option grant covering 300,000 shares of common stock at an exercise price of $5.71 per share on January 30, 2026. The option vests 25% on January 30, 2027, then 6.25% of the shares on the first day of each calendar quarter until fully vested, and is exercisable until January 29, 2036.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider Bellon Steven F.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	300,000	$5.71	$1.71M

Holdings After Transaction: Stock Option (right to buy) — 300,000 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 300,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Foghorn Therapeutics (FHTX) disclose about Steven Bellon’s equity compensation?

Foghorn Therapeutics disclosed that Chief Scientific Officer Steven F. Bellon received a stock option for 300,000 shares at $5.71 per share. This award gives him the right to buy common stock if he satisfies the vesting schedule and exercises before the January 29, 2036 expiration.

How many FHTX shares are covered by Steven Bellon’s new stock option?

The new stock option granted to Steven Bellon covers 300,000 shares of Foghorn Therapeutics common stock. These shares are not issued immediately; they become purchasable only as the option vests over time and if he chooses to exercise at the stated exercise price.

What is the exercise price of Steven Bellon’s FHTX stock option grant?

The exercise price of Steven Bellon’s stock option grant is $5.71 per share. This means he can buy up to 300,000 Foghorn Therapeutics common shares at $5.71, once vested, regardless of the market price at the time of exercise, until expiration.

How does the vesting schedule work for Steven Bellon’s 300,000 FHTX options?

The option vests 25% of the underlying shares on January 30, 2027. After that, it vests an additional 6.25% of the underlying shares on the first day of each calendar quarter, creating a stepped schedule until all 300,000 underlying shares are fully vested.

When does Steven Bellon’s FHTX stock option expire?

Steven Bellon’s stock option expires on January 29, 2036. He may exercise vested portions any time after they vest and before this expiration date, subject to the plan’s terms and any applicable company or regulatory restrictions on exercising stock options.

Is Steven Bellon’s ownership in FHTX direct or indirect after this option grant?

The filing shows Steven Bellon’s beneficial ownership of these derivative securities as direct. Following the grant of 300,000 stock options, the number of derivative securities beneficially owned after the reported transaction is 300,000, all listed under direct ownership in the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellon Steven F.

(Last) (First) (Middle)

99 COOLIDGE AVENUE

SUITE 500

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.71	01/30/2026		A		300,000		(1)	01/29/2036	Common Stock	300,000	$5.71	300,000	D

Explanation of Responses:

1. The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.

Remarks:

	/s/ Michael LaCascia, Attorney-in-Fact for Steven F. Bellon	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.